163 related articles for article (PubMed ID: 21888562)
1. Outbreak caused by Proteus mirabilis isolates producing weakly expressed TEM-derived extended-spectrum β-lactamase in spinal cord injury patients with recurrent bacteriuria.
Cremet L; Bemer P; Rome J; Juvin ME; Navas D; Bourigault C; Guillouzouic A; Caroff N; Lepelletier D; Asseray N; Perrouin-Verbe B; Corvec S
Scand J Infect Dis; 2011 Dec; 43(11-12):957-61. PubMed ID: 21888562
[TBL] [Abstract][Full Text] [Related]
2. Molecular epidemiology of CTX-M-type extended-spectrum β-lactamase-producing Proteus mirabilis isolates in Taiwan.
Huang CW; Chien JH; Peng RY; Tsai DJ; Li MH; Lee HM; Lin CF; Lee MC; Liao CT
Int J Antimicrob Agents; 2015 Jan; 45(1):84-5. PubMed ID: 25446905
[No Abstract] [Full Text] [Related]
3. Molecular diversity of Proteus mirabilis isolates producing extended-spectrum beta-lactamases in a French university hospital.
Biendo M; Thomas D; Laurans G; Hamdad-Daoudi F; Canarelli B; Rousseau F; Castelain S; Eb F
Clin Microbiol Infect; 2005 May; 11(5):395-401. PubMed ID: 15819867
[TBL] [Abstract][Full Text] [Related]
4. The first detection of CTX-M-14 extended-spectrum beta-lactamase among diverse beta-lactamase-producing Proteus mirabilis clinical isolates.
Yong D; Lim YS; Roh KH; Choi YS; Park DY; Yum JH; Kim JM; Lee K; Chong Y
Diagn Microbiol Infect Dis; 2006 Mar; 54(3):237-9. PubMed ID: 16427241
[TBL] [Abstract][Full Text] [Related]
5. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
Kanayama A; Iyoda T; Matsuzaki K; Saika T; Ikeda F; Ishii Y; Yamaguchi K; Kobayashi I
Int J Antimicrob Agents; 2010 Oct; 36(4):340-2. PubMed ID: 20609568
[TBL] [Abstract][Full Text] [Related]
6. Nosocomial outbreak by Proteus mirabilis producing extended-spectrum beta-lactamase VEB-1 in a Korean university hospital.
Kim JY; Park YJ; Kim SI; Kang MW; Lee SO; Lee KY
J Antimicrob Chemother; 2004 Dec; 54(6):1144-7. PubMed ID: 15546971
[TBL] [Abstract][Full Text] [Related]
7. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.
Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A
Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415
[TBL] [Abstract][Full Text] [Related]
8. A binational cohort study of intestinal colonization with extended-spectrum β-lactamase-producing Proteus mirabilis in patients admitted to rehabilitation centres.
Adler A; Baraniak A; Izdebski R; Fiett J; Gniadkowski M; Hryniewicz W; Salvia A; Rossini A; Goossens H; Malhotra S; Lerman Y; Elenbogen M; Carmeli Y;
Clin Microbiol Infect; 2013 Feb; 19(2):E51-8. PubMed ID: 23210906
[TBL] [Abstract][Full Text] [Related]
9. Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 beta-lactamases at 2 hospitals in Taiwan.
Wu LT; Wu HJ; Chung JG; Chuang YC; Cheng KC; Yu WL
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):89-94. PubMed ID: 16406185
[TBL] [Abstract][Full Text] [Related]
10. [The incidence of extended spectrum beta-lactamases in Proteus mirabilis strains isolated in 2007-2009].
Kwiecińska-Piróg J; Bogiel T; Gospodarek E
Przegl Epidemiol; 2010; 64(3):395-8. PubMed ID: 20976952
[TBL] [Abstract][Full Text] [Related]
11. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases.
Aragón LM; Mirelis B; Miró E; Mata C; Gómez L; Rivera A; Coll P; Navarro F
J Antimicrob Chemother; 2008 May; 61(5):1029-32. PubMed ID: 18292096
[TBL] [Abstract][Full Text] [Related]
12. High prevalence and molecular characterization of extended-spectrum β-lactamase-producing Proteus mirabilis strains in southern Croatia.
Tonkić M; Mohar B; Šiško-Kraljević K; Meško-Meglič K; Goić-Barišić I; Novak A; Kovačić A; Punda-Polić V
J Med Microbiol; 2010 Oct; 59(Pt 10):1185-1190. PubMed ID: 20558587
[TBL] [Abstract][Full Text] [Related]
13. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases.
Endimiani A; Luzzaro F; Brigante G; Perilli M; Lombardi G; Amicosante G; Rossolini GM; Toniolo A
Antimicrob Agents Chemother; 2005 Jul; 49(7):2598-605. PubMed ID: 15980325
[TBL] [Abstract][Full Text] [Related]
14. Clonal outbreak caused by VIM-4-producing Proteus mirabilis in a Greek tertiary-care hospital.
Protonotariou E; Poulou A; Politi L; Meletis G; Chatzopoulou F; Malousi A; Metallidis S; Tsakris A; Skoura L
Int J Antimicrob Agents; 2020 Aug; 56(2):106060. PubMed ID: 32574790
[TBL] [Abstract][Full Text] [Related]
15. Emergence of Proteus mirabilis isolates producing TEM-52 extended-spectrum beta-lactamases in Croatia.
Sardelić S; Bedenić B; Sijak D; Colinon C; Kalenić S
Chemotherapy; 2010; 56(3):208-13. PubMed ID: 20551637
[TBL] [Abstract][Full Text] [Related]
16. Occurrence of extended-spectrum (beta)-lactamases and plasmid-mediated AmpC (beta)-lactamases among Korean isolates of Proteus mirabilis.
Park YJ; Lee S; Kim YR; Oh EJ; Woo GJ; Lee K
J Antimicrob Chemother; 2006 Jan; 57(1):156-8. PubMed ID: 16284101
[No Abstract] [Full Text] [Related]
17. Epidemiology of Escherichia coli, Klebsiella species, and Proteus mirabilis strains producing extended-spectrum β-lactamases from clinical samples in the Kinki Region of Japan.
Nakamura T; Komatsu M; Yamasaki K; Fukuda S; Miyamoto Y; Higuchi T; Ono T; Nishio H; Sueyoshi N; Kida K; Satoh K; Toda H; Toyokawa M; Nishi I; Sakamoto M; Akagi M; Nakai I; Kofuku T; Orita T; Wada Y; Zikimoto T; Koike C; Kinoshita S; Hirai I; Takahashi H; Matsuura N; Yamamoto Y
Am J Clin Pathol; 2012 Apr; 137(4):620-6. PubMed ID: 22431539
[TBL] [Abstract][Full Text] [Related]
18. Regional outbreak of CTX-M-2 β-lactamase-producing Proteus mirabilis in Japan.
Nakano R; Nakano A; Abe M; Inoue M; Okamoto R
J Med Microbiol; 2012 Dec; 61(Pt 12):1727-1735. PubMed ID: 22935848
[TBL] [Abstract][Full Text] [Related]
19. Clinical epidemiology of ciprofloxacin-resistant Proteus mirabilis isolated from urine samples of hospitalised patients.
Saito R; Okugawa S; Kumita W; Sato K; Chida T; Okamura N; Moriya K; Koike K
Clin Microbiol Infect; 2007 Dec; 13(12):1204-6. PubMed ID: 17850340
[TBL] [Abstract][Full Text] [Related]
20. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A
Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
